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Background: Drug repurposing for cancer treatment is an emerging approach to discover clinically approved
drugs that demonstrate antineoplastic effect. The effective therapeutics for patients with advanced adrenocortical
carcinoma(ACC) are greatly needed. The objective of this study was to identify and validate drugs with
antineoplastic effect in ACC cells using a novel quantitative high-throughput drug screening (qHTS) technique.
Methods: A quantitative high-throughput proliferation assay of 2,816 clinically approved drugs was performed in
the NCI-H295R ACC cell line. We validated the antiproliferative effect of candidate compounds in NCI-H295R cells.
Further validation was performed in 3-dimensional multicellular aggregates (MCA) of NCI-H295R and SW-13 cell
lines.
Results: We identified 79 active compounds against ACC cells; 21 had an efficacy ≥60% and IC50 <1 μM. The top
drug categories enriched were cardiotonic, antiseptic, and antineoplastic. We selected Bortezomib, ouabain,
Methotrexate, pyrimethamine for validation. All had an antiproliferative effect in monolayer culture of NCI-H295R
cells at clinical achievable serum level. Bortezomib and ouabain inhibited growth of MCA in both cell lines at a low
concentration (10 fold below IC50). Methotrexate inhibited growth and caused disintegration of MCA in both cell
lines at concentrations well below the maximum serum level (10 to 100 fold of IC50). Pyrimethamine caused growth
inhibition in both cell lines at 10 fold of IC50 concentration.
Conclusions: qHTS of previously approved compounds is an effective and efficient method to identify anticancer
drugs for a rare cancer such as ACC. We have validated the antineoplastic effect of Bortezomib, ouabain,
Methotrexate and pyrimethamine, which could be translated into clinical trials in patients with locally advanced
and/or metastatic ACC.
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Adrenocortical cancer (ACC) is a rare and aggressive
malignancy. Patients with ACC generally have a dismal
prognosis, with only 16% to 38% 5-year survival rate [1,2].
While surgical resection may cure some patients with
localized disease, most patients present with advanced
disease or develop local recurrence and distant metas-
tasis after surgery [3]. Five-year disease specific survival* Correspondence: niluboln@mail.nih.gov
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reproduction in any medium, provided the orvaries depending on several prognostic factors, ranging
from 9% to 60% [3,4]. Unfortunately, there is no effect-
ive therapy that provides a durable objective response
in patients with advanced and metastatic ACC.
Although there has been an increased focus on perso-
nalized treatment in the post-genomic era, this approach
is in its infancy for ACC as the genetic causes are poorly
understood. The cost and time needed for developing a
new therapy for rare cancers are also often prohibitive.
An alternative approach to cancer therapy that is just be-
ginning to be explored is the exploitation of established
drugs that have already been approved for clinical use forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Nilubol et al. Journal of Translational Medicine 2012, 10:198 Page 2 of 15
http://www.translational-medicine.com/content/10/1/198one or more indications and with known toxicity. Drug
“repositioning”, “repurposing” or “indication switching”
has several important advantages that circumvent other
traditional drug discovery approaches [5-7]. Since the
pharmacokinetic, pharmacodynamic, and toxicity profiles
of the drugs are well known, an immediate translation
into phase II or III clinical trial to test the efficacy can be
performed. In addition, potential new mechanisms of
drug action against tumor cells or biological process
involved in carcinogenesis can be further explored. Fur-
thermore, some drugs found to have an anticancer effect
may reduce the risk of developing cancer and thus could
be used for prevention of common cancers in high risk
individuals [8-11]. Given these inherent advantages of
drug repurposing and the lack of effective therapy for
ACC, we performed quantitative high throughput
screening (qHTS) of 2,816 clinical approved drugs in the
NCI-H295R ACC cell line. We then validated a select
number of drugs in 3-dimensional multicellular aggre-
gates (MCA) of NCI-H295R and SW-13 ACC cell lines.
Materials and methods
ACC cell culture
NCI-H295R cells and SW-13 cells were both grown and
maintained in Dulbecco modified Eagle medium
(DMEM) supplemented with 0.1% premix ITS+ (BD
Biosciences, San Jose, CA), and serum (Nu-Serum I
[2.5%], BD Biosciences, San Jose, CA) in a standard hu-
midified incubator at 37°C in a 5% CO2 atmosphere.
Cells were routinely sub-cultured every 3 to 4 days. The
establishment and characterization of NCI-H295R and
SW-13 cell lines were described by Gazdar et al. [12]
and Leibovitz et al. [13], respectively. NCI-H295 cells
originated from adrenal cortex of a 48 year-old African
American female patient with adrenocortical carcinoma.
NCI-H295R was adapted from the NCI-H295 pluripo-
tent ACC cell line established by Gazdar et al [12]. The
original cells were adapted to a culture medium which
resulted in a decreased population doubling time from
5 days to 2 days. While the original cells grew in suspen-
sion, the adapted cells were selected to grow in a mono-
layer. This cell line retains the ability to produce adrenal
androgens, aldosterone and cortisol. It is responsive to
angiotensin II and potassium ions. SW-13 cells origi-
nated from adrenal cortex of a 55 year-old Caucasian fe-
male with metastatic primary small cell adrenal
carcinoma [13]. Itoh et al. demonstrated an increase pro-
duction of dehydroepiandrosterone sulfate (DHEA-S) by
angiotensin-II administration in SW-13 cell line, consist-
ent with steroidogenesis in human adrenal cortex [14].
However, SW-13 cells do not produce cortisol and only
produce very small amount of aldosterone [15].
Both cell lines were purchased from American Type
Tissue Collection™ (Manassas, VA) and authenticated byShort Random Repeat profiling. The Short Random Re-
peat profiles are the product of polymerase chain reac-
tion using the commercially available Promega
PowerPlex 1.2 kit (Promega North America, Madison,
WI) with AmpliTaq Gold polymerase (Applied Bios
stems, Foster City, CA) and 1 ng of template DNA. Our
NCI-H295R cells used in initial high throughput screen-
ing process were in their 5th passage from original cells
received from the American Type Tissue Collection™.
We subsequently confirmed cortisol production by
ELISA in our NCI-H295R cell line in later passages.
National institutes of health chemical genomic center
(NCGC) pharmaceutical library screening
The NCGC Pharmaceutical Collection (NPC) consists of
2,816 small molecule compounds with 52% of the drugs
approved for human or animal use by the United States
Food and Drug Administration (FDA) The list of 2,816
compounds is provided in Additional file 1. The
remaining drugs are either approved for use in other
countries, such as Europe, Canada, or Japan, or are com-
pounds that have been tested in clinical trials. Additional
detailed information on the drug library can be found at
http://tripod.nih.gov/npc/.
The compounds from NPC library were prepared as
15 interpolate titrations, which were serially diluted
1:2.236 in dimethyl sulfoxide (DMSO) (Thermo Fisher
Scientific, Waltham, MA) in 384-well plates. The stock
concentrations of the test compounds ranged from
10 mM to 0.13 μM. The transfer of the diluted com-
pounds from 384-well plates to 1536-well plates was
performed using an Evolution P3 system (PerkinElmer
Life and Analytical Sciences, Waltham, MA). Each treat-
ment plate included concurrent DMSO, top concen-
trated positive control wells and concentration-response
titrations of positive controls, all occupying columns 1
to 4. Each compound was tested in duplicates. During
screening, the compound plates were thawed, sealed and
kept at room temperature. After NCI-H295R cells were
treated, cells were kept in the incubator for 48 hours.
Quantitative high throughput proliferation assay
Cell viability after drug treatment was measured using a
luciferase-coupled ATP quantization assay (CellTiter-
GloW, Promega, Madison, WI) in NCI-H295R cells. The
change of intracellular ATP content indicates the num-
ber of metabolically competent cells after drug treat-
ment. NCI-H295R cells were harvested from T225 flask
and resuspended in ITS supplemented DMEM serum
free medium at a concentration of 300,000 cells/ml.
Then 5 μl of resuspended cells was dispensed into each
well of white, solid bottom, 1536-well tissue culture–
treated plates using a Multidrug Combo dispenser. After
overnight culture at 37°C with 5% CO2, a total of 23 nl
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NPC or positive control (10 mM stock of doxorubicin
hydrochloride) in DMSO was transferred to each well of
the assay plate using a pin tool (Kalypsys, San Diego,
CA). The final concentration of the compounds in the
5 μl assay volume ranged from 0.6nM to 46 μM with a
1:5 dilution factor.
We performed cell density testing by seeding 500,
1000, 1500, and 2000 cells per well. The cell density that
provided optimal dose–response curve was 1500 cells
per well (Figure 1A). At 2,000 cells per well, cellular
proliferation was observed in vehicle control group
(DMSO) at 48 hours, suggesting sufficient growth condi-
tion (Figure 1B). The plates were further incubated at
37°C and 5% CO2 for 48 hours. Then 4 μl of CellTilter-
GloWluminescent substrate mix (Promega, Madison, WI)
was added to each well. The plate was incubated at
room temperature for 20 minutes. A ViewLux plate
reader (PerkinElmer, Waltham, MA) with clear filter wasFigure 1 A) NCI-H295R cell density testing for quantitative high throu
curve was observed. B) At 2,000 cells per well, cellular proliferation was obsused to measure the number of metabolically competent
cells. The experiment was performed once.
To determine compound activity in the qHTS assay,
the titration-response data for each sample was plotted
and modeled by a four parameter logistic fit yielding
IC50 and efficacy (maximal response) values. Raw plate
reads for each titration point were first normalized rela-
tive to positive control (doxorubicin hydrochloride,
100% inhibition) and DMSO only wells (basal, 0%). The
screening performance was evaluated by 1) coefficient of
variation (CV) defined as the standard deviation of com-
pound area (the area from the 5th to 48th column in
1536-well plate where the compounds from NCGC
pharmaceutical library are plated and tested) to the
mean of compound area. The acceptance criterion is
met when the CV of each signal is≤ 20% for DSMO and
low concentration plates, high concentration plates
(plate # 9, 10, 19 and 20) in Additional file 2: Figure S1
were not applied, 2) signal-to-background (S/B) ratio.ghput screening. At 1,500 cells per well, the optimal dose–response
erved in DMSO treated NCI-H295R cells.
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of statistical effect size as described by Zhang et al [16].
In brief, Z = 1 is an ideal assay where no variation (stand-
ard deviation = 0) or dynamic range is infinite, Z between
0.5 and 1.0 is an excellent assay, Z between 0 and 0.5 is
a marginal assay, and Z < 0 is not a useful assay.
We selected the candidate compounds that demon-
strated antiproliferative efficacy of > 60% and IC50 < 1 μM
for further validation. Compounds that meet our criteria
are likely to have antineoplastic activity against ACC at
clinically achievable serum level. We then analyzed the
characteristics of these drugs, including the current avail-
able preparation and route of administration, maximum
serum concentrations after systemic delivery, and drug
half-life in humans (Table 1). We selected 4 active drugs
that could be administered orally or intravenously with
IC50 equal to or below maximal serum concentration for
validation. To further assess the drug categories that
were active against NCI-H295R, we performed enrich-
ment analysis by therapeutic category. The enrichment
score is the ratio of number of active drugs to the total of
numbers of tested drugs in the same therapeutic






Aclarubicin IV 0.94 0.34
Actinomycin D IV 0.38 0.02-0.08
Bortezomib IV 0.34 0.16-0.31
Carboquone PO/IV 0.75 0.62-0.74 (200-240 ng/mL)
Ciclopirox Topical 0.64 N/A - topical only
Deslanoside 0.34 0.16
Digitoxin IV 0.08 0.05-0.2
Digoxin PO/IV 0.19 0.003
Ecteinascidin IV 0.01 Up to 0.05
Homoharringtonine SQ 0.21 0.176
Lanatoside A IV/PO 0.19 N/A
Lanatoside C IV/PO 0.3 N/A
Methotrexate PO/IV 0.02 10-100
Metildigoxin PO/IV 0.24 N/A
Niclosamide PO/IV 0.27 N/A
Ouabain IV 0.08 0.128
Plicamycin IV 0.94 0.6 μM
Proscillaridin A IV/PO 0.01 0.019 (IV); 0.0019 (PO)
Pyrimethamine PO/IV 0.75 8.04
Rotenone N/A 0.75 N/A
Trimetrexate glucuronate IV 0.01 N/A
1The references for this table are provided in Additional file 3.
N/A: no available data.We explored the use of qHTS as a tool to screen for
compounds with antiproliferative activity in normal cells
or in other cancer cells by assessing the activities of ac-
tive drugs in the following normal and cancer cell lines:
TPC-1: papillary thyroid cancer cell line, NF-kB: ME-
180 human cervical carcinoma cell line, MRC5: normal
human fetal lung fibroblasts, Mesangial: human kidney
glomerular mesangial cell line, LAM: lymphoangioleio-
myosis cell line (LAM, a rare lung disease that results in
a proliferation of disorderly smooth muscle growth)
(Figure 2B).
In vitro validation of qHTS assay























11The candidate drugs with antiproliferative activity
were validated in NCI-H295R ACC cells using the
CyQuantW Cell Proliferation Assay (InvitrogenTM
Corp., Carlsbad, CA). NCI-H295R (6 × 103) cells
were plated into 96-well clear bottom, black plate
(CostarW, Corning, NY). Each well contained 100 μl
of culture media with serum. After 24 hours (Day 0),
100 μl of fresh culture media containing doubleR cells with efficacy higher than 60% and potency
imination
lf life
Efficacy Mode of action
.3 hrs -122.30 Topoisomerase I and II inhibitor
hrs -112.51 Inhibitors of DNA synthesis
15 hrs -77.11 Proteasome inhibitor;
5 hrs -119.79 Alkylating agents
2 hrs in rabbits -61.11 Chelation of polyvalent metal cations
hrs -110.35 Na+/K +ATPase inhibition;
9 days -109.13 Na+/K + ATPase inhibition;
-48 hrs -111.40 Na+/K + ATPase inhibition;
-180 hrs -116.82 Disruption of DNA strand
3 hrs -125.33 Protein synthesis inhibitor
/A -114.10 Na+/K + ATPase inhibition;
/A -117.82 Na+/K + ATPase inhibition;
15 hrs -74.91 DHFR inhibitor
/A -110.90 Na+/K + ATPase inhibition;
/A -94.29 Uncouple oxidative phosphorylation
hrs -110.64 Na+/K + ATPase inhibition;
.5 hrs -117.62 RNA synthesis inhibitor;
-33 hrs -110.55 Na+/K + ATPase inhibition;
0-190 hrs -81.43 DHFR inhibitor
/A -69.22 Electron transport chain in
mitochondria interference
-16 hrs -80.39 DHFR inhibitor
Figure 2 A) Enrichment analysis of screened active compounds by therapeutic category. B) Drug activity profile across different cell lines
and primary cell culture of 21 active drugs in H295R cells. Black box indicates active compound, grey box indicates compound with inconclusive
activity, white box represents inactive compounds, and the compounds that were not tested are labeled in stripe. The criteria for compound
activity are described in Data Analysis section. TPC-1: papillary thyroid cancer cell line, NF-kB: ME-180 human cervical carcinoma cell line, MRC5:
normal human fetal lung fibroblasts, Mesangial: human kidney glomerular mesangial cell line, LAM: lymphoangioleiomyosis cell line (LAM, a rare
lung disease that results in a proliferation of disorderly smooth muscle growth). C) Dose–response curve of NCI-H295R treated with cisplatinum,
etoposide and mitotane.
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corresponding vehicles was added into each well.
Additional 100 μl of fresh media containing the 1×
concentration of the tested drugs or vehicles were
added 48 hours (Day 2) after initial administration to
support optimal cell growth. We treated the cells
with 3 concentrations of each selected drugs as well
as their respective vehicle controls based on their
half maximal inhibitory concentration (IC50) fromthe qHTS. The three concentrations used were 10
fold of IC50, IC50, and 0.1 fold of IC50. Each
concentration was performed in quadruplicates.
CyQuantW Cell Proliferation Assay (InvitrogenTM
Corp., Carlsbad, CA) was performed on Day 0, 1, 2,
3 and 4 according to the manufacturer’s protocol.
The cell densities in the 96-well black plates were
determined using a SpectraMax M5e 96-well
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tested, the experiments were repeated at least three
times. We selected the concentrations of the drugs
that demonstrated antiproliferative effect in NCI-
H295R cells and validated the in SW-13 cells. SW-13
(4 × 103) cells were plated into 96-well plate and
tested using the same cell proliferation assay
protocol.2. In vitro validation of candidate drugs in
3-dimensional multicellular aggregates (MCA).
Further validation tests of the candidate drugs were
performed on MCA of NCI-H295R and SW-13 cells.
Although monolayer cell cultures can provide
cell-specific response to drugs, this model, however,
lacks the microenvironment of 3-dimentional solid
tumors observed in vivo, such as hypoxic tissue
areas, regions of differential growth and cell cycling,
as well as poor availability of delivered drugs in
deeper tumor tissue layers, which can be found
in MCA[17].
MCA of NCI-H295R cells form compact tumor
spheroids in suspension culture condition. We
generated NCI-H295R tumor spheroids by plating
1.0 × 105cells/well into Ultra Low Cluster, 24-well
plate (CostarW, Corning, NY) and incubated the cells
at 37°C in 5% CO2 for two weeks. The media was
changed twice a week. At the beginning of the 3rd
week of culture, NCI-H295R MCA were treated with
selected drugs and their corresponding vehicle
controls using concentrations based on IC50 from the
monolayer proliferation assay and maximal serum
levels (Table 2).
SW-13 cells form 3-dimensional cell growth with the
cell aggregates were not as tight and compact as
MCA formed by NCI-H295R. We utilized the same
protocol described above to grow SW-13 MCA.
SW-13 MCA were treated with selected drugs at the
beginning of the 4th week of culture to allow the cells
to form denser aggregates. All the concentrations of
selected drugs and their corresponding vehicle
controls were identical to those used in NCI-H295R
MCA (Table 2).
All experiments were performed in triplicates for
each testing concentration. SW-13 and H295R MCAle 2 Drug concentrations tested in NCI-H295R and SW-13 MCA
s IC50





: 3-dimensional multicellular aggregates.
half maximal inhibitory concentration.
c: concentrations.were continuously treated for 6 and 10 weeks,
respectively. MCA were photographed with Nikon
coolpix 990 with Nikon MDC lens (Nikon, Inc,
Melleville, NY) under 12.5× magnification
microscope (Olympus SZX9 microscope with DF
Plapo 1X-2 lens, Olympus America, Inc, Center
Valley, PA). The experiments were repeated at least
twice. A quantitative analysis of MCA was performed
by measuring the area of MCAs using Image
software (National Institutes of Health, Bethesda,
Maryland, USA, http://rsb.info.nih.gov/ij/,
1997-2008).Caspase-3 and -7 activation assay
The effect of Bortezomib, ouabain, Methotrexate and
pyrimethamine on caspase 3 and 7 activity was evaluated
using the Caspase-GloW 3/7 kit (Promega North Amer-
ica, Madison, WI) according to the instructions provided
by the manufacturer. Briefly, NCI-H295R cells (6 × 103
cells/well in 100 μl) were placed in a 96-well white
walled clear bottom plate (Lonza, Allendale, NJ). Cells
were incubated for 24 hours then treated with
1) 0.34 μM Bortezomib (IC50), 2) 0.08 μM ouabain
(IC50), 3) 0.2 μM Methotrexate (10-fold of IC50), and 4)
7.5 μM pyrimethamine (10-fold of IC50) and their re-
spective vehicle controls.
The Caspase-GloW 3/7 reagent (100 μl/well) was added
at 48 and 72 hours post-treatment. The plates were incu-
bated in the dark for 60 minutes at room temperature on
plate shaker. Luminescence was measured in SpectraMax
M5e plate reader (Molecular Devices, Sunnyvale, CA).
All the treatments were performed in quadruplicates.
The caspase activity of treated NCI-H295R cells was
compared to vehicle controls. Data are presented as
mean ratio of caspase activity in treated cells to vehicle
controls ± SD.
Cell cycle analysis
SW-13 and NCI-H295R cells were plated in 75 cm2 tis-
sue culture flasks at 5 × 105 and 1 × 106 cells per flask,
respectively. Cells were incubated for 24 hours, culture
medium was removed, and 15 ml fresh culture medium
containing vehicle controls or fresh medium with 200
nM Methotrexate or 7.5 μM pyrimethamine was added1
Conc3. tested in MCA (μM) Ratio of tested conc. to IC50
3.4, 0.34, 0.17, 0.03 10x, 1x, 0.5x, 0.1x
0.8, 0.16, 0.08 10x, 2x, 1x
2, 1, 0.2 100x, 50x, 10x
7.5, 3.7 10x, 5x
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washed, resuspended with PBS, and fixed with ice-cold
70% ethanol at 4°C. After washing with PBS, rib nuclease
A was added to the cell suspension and incubated at 37°C
for 30 min. Propidium iodide (PI) (50 mg/ml in PBS) was
added, and samples were stored at 4°C until analysis.
Flow cytometry analysis for cell cycle was performed on
a FACScan using CellQuest software (BD Biosciences,
San Jose, CA). Data files were generated for more than
20,000 events (cells) per sample gated on singlet cells.
Cell clumps, debris, and doublets were excluded by PI
fluorescence pulse width and pulse area measurements.
Cell cycle analysis on the gated PI distribution was per-
formed using Modify software (Verity Software House,
Inc., Topsham, ME).
Data analysis
For the high throughput screening assay, the titration-
response data of each sample were plotted and modeled
by a four-parameter logistic fit to determine compound
activity [18]. Curve-fits were then classified by criteria
previously described [18]. In brief, Class 1.1 and 1.2 were
full curves containing upper and lower asymptotes with
efficacy≥ 80% and < 80%, respectively. Class 2.1 and 2.2
were incomplete curves having only one asymptote with
efficacy≥ 80% and< 80%, respectively. Class 3 curves
showed activity at only the highest concentration or were
poorly fit. Class 4 curves were inactive having a curve-fit
of insufficient efficacy or lacking a fit altogether. Only
compounds that demonstrated Class 1.1, 1.2, 2.1, and 2.2
with the maximal inhibition over 60% were considered
active against NCI-H295R cells. Compounds that demon-
strated Class 2.2 with the maximal inhibition ≤60% or
Class 3 curve were considered inconclusive with low con-
fidence activity.
Cell proliferation assay was analyzed using the paired
t test to determine the statistical difference between the
density of treated cells and corresponding vehicle con-
trol. The area of MCA was compared using the paired
t test. The two-sided p value less than 0.05 was consid-
ered statistically significant.
Results
Quantitative high throughput screening of clinical drug
library
Overall performance of qHTS was excellent with low
variation, high S/B ratio and Z-factor between 0.5 to 1.
The screening performance and plate variation are sum-
marized in Additional file 2: Figure S1. The quantitative
high throughput screening identified 79 high-confidence,
active compounds (Class 1.1, 1.2, 2.1, and 2.2 with the
maximal inhibition over 60%) in the NCI-H295R cell
line (Additional file 4: Table S1.). Twenty one of these
compounds had efficacy higher than 60% and potency(IC50) below 1 μM. These 21 compounds were distribu-
ted across various therapeutic categories and mode of
actions (Table 1). Top 5 drug categories active in the
NCI-H295R cells (enrichment ratio >15%) demonstrated
by the enrichment analysis were cardiotonic, antiseptic,
antineoplastic, immunosuppressant, and anthelmintic
(Figure 2A). Eight of 21 active compounds with >60% ef-
ficacy were cardiac glycosides (Table 1). The antiproli-
ferative activity of the 21 active compounds against
NCI-H295R cells was further analyzed to evaluate the
cross activity in other types of normal and cancer cell
lines. To evaluate the concept that qHTS can be used to
screen drug toxicities in normal cells to guide compound
selection, we tested 11 of 21 compounds with activity
against NCI-H295R cells in MRC5 and mesangial cells
and found that eight showed no antiproliferative or low-
confidence activity, which suggests that these drugs had
specific antiproliferative activity in particular normal and
tumor cells. When compared to other cancer types, a
distinct activity pattern was also observed for NCI-
H295R cells, in which several of the drugs were also ac-
tive against other cancer cells, but they usually showed
less activity or even no antiproliferative effect in cervical
cancer cells (NF-kB) (Figure 2B).
Validation of candidate active compounds
Based on our selection criteria, 4 promising drugs (Bor-
tezomib, ouabain, methotrexate and pyrimethamine)
were chosen for validation (Table 2). All had IC50 equal
to or below maximum serum concentration in human
with antiproliferative efficacy >60%.
Drugs that are known to induce tumor response clin-
ically such as mitotane, cisplatinum and etoposide were
in our qHTS drug library [19]. Cisplatinum was not ac-
tive against NCI-H295R. Mitotane and etoposide only
showed antiproliferative effect at high concentration
with single point activity (class 3 curve). Dose–response
curve of cisplatinum, mitotane and etoposide are shown
in Figure 2C.
We validated the antiproliferative effect of these 4
drugs from the qHTS in NCI-H295R monolayer cell cul-
ture. Bortezomib is the first FDA-approved proteasome
inhibitor for treatment of mantle cell lymphoma and
multiple myeloma. Bortezomib demonstrated remark-
able effect on cellular proliferation at concentrations as
low as 34 nM (0.1 fold of IC50) (Figure 3A). At 34 nM,
Bortezomib not only result in 68% growth inhibition,
but also caused cell death 11%. The growth inhibition ef-
fect was dose-dependent (340 nM and 3.4 μM)
(Figure 3A). At 340nM (IC50), Bortezomib inhibited cel-
lular proliferation of SW-13 cells by 65% at day 4
(Figure 3E).
Once the antiproliferative effect of Bortezomib was
confirmed in monolayer cell culture, we tested the effect
Figure 3 Cell proliferation assay of NCI-H295R treated with bortezomib (A), ouabain (B), methotrexate (C), and pyrimethamine (D).
Selected effective concentrations of bortezomib, ouabain, methotrexate, and pyrimethamine from cell proliferation assay of NCI-H295R were
validated in SW-13 (E). The error bar indicates the ranges of cell numbers. * p value <0.05 but≥ 0.01, ** p value < 0.01.
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MCA of NCI-H295R and SW-13 cells treated with
Bortezomib were significantly smaller at all concentra-
tions (Figure 4A and Table 3).
Ouabain is a cardiac glycoside that inhibits Na+/K +
ATPase. The antiproliferative effect was validated in
NCI-H295R monolayer cell cultures and MCA of both
cell lines. At 0.08 μM and 0.8 μM (IC50 and 10 fold of
IC50, respectively), ouabain demonstrated an antiproli-
ferative effect in NCI-H295R cells with 57% and 89%
growth inhibition, respectively. Both concentrations of
ouabain also caused cell death by 13% and 77%
(Figure 3B). At 0.08 μM (IC50), ouabain inhibited cellular
proliferation of SW-13 cells with 62% cell death at day 4
(Figure 3E). At 0.08 μM, 0.16 μM and 0.8 μM (1 fold, 2Figure 4 Three-dimensional multicellular aggregates (MCA) of NCI-H2
methotrexate (4C), and pyrimethamine (4D). Cells treated with bortezom
disintegration of MCAs. Pyrimethamine treated SW13 cells developed noticfold and 10 fold of IC50, respectively), ouabain inhibited
growth and MCA in both cell lines were significantly
smaller. Disintegration of MCA occurred in SW-13
MCA at all concentrations (Figure 4B and Table 3).
Methotrexate is a dihydrofolate Reductase (DHFR) in-
hibitor with antineoplastic and immunomodulator
effects. The antiproliferative effect of methotrexate was
validated only when NCI-H295R cells in monolayer cul-
ture were treated with a concentration of 0.2 μM (10
fold of IC50) (Figure 3C). At 0.2 μM (10 fold of IC50),
methotrexate demonstrated antiproliferative effect in
SW-13 cells (Figure 3E). However, Methotrexate has a
very high therapeutic range (10 to 100 μM) and the
maximal serum level achievable is over 500 fold of IC50
in the qHTS. Thus, we evaluated the antiproliferative95R and SW13 treated with bortezomib (4A), ouabain (4B),
ib, ouabain, and methotrexate had noticeably smaller MCAs or
eably smaller MCAs. Pyrimethamine had no effect on NCI-H295R MCAs.
Table 3 The area of NCI-H295R and SW-13 MCAs treated with various concentrations of bortezomib, oubain,
methotrexate and 7.5 μM pyrimethamine was significantly smaller than respective controls
Drugs and concentrations tested
in (ratio to IC50
2
)
Area of NCI-H295R MCAs
(Mean pixels ± SD)
p-value Area of SW-13 MCAs
(Mean pixels ± SD)
p-value
Bortezomib 0.1% DMSO 2.3 ± 0.7x105 0.02 8.2 ± 2.4x105 0.03
3.4 μM 0(10x), 10.7 ± 0.8x105 1.0 ± 0.3x105
0.01% DMSO 2.6 ± 0.9x105 0.048 1.1 ± 0.2x106 0.02
0.34 μM (1x), 1.3 ± 0.2x105 1.8 ± 0.2x105
0.005% DMSO 2.3 ± 0.5x105 0.01 8.3 ± 1.7x105 0.015
0.17 μM (0.5x) 1.3 ± 0.2x105 1.0 ± 0.2x105
0.001% DMSO 3.0 ± 0.6x105 <0.01 7.5 ± 1.2x105 0.01
0.03 μM (0.1x) 1.6 ± 0.1x105 5.0 ± 1.6x104
Ouabain Media only 2.4 ± 0.07x105 0.01 1.0 ± 0.2x106 0.01
0.8 μM (10x) 1.5 ± 0.1x105 1.0 ± 0.2x105
0.16 μM (2x) 1.6 ± 0.2x105 0.03 1.4 ± 0.1x105 0.01
0.08 μM (1x) 1.6 ± 0.2x105 <0.01 1.1 ± 0.7x105 <0.01
Methotrexate 0.1% DMSO 2.0 ± 0.2x105 <0.01 7.8 ± 0.5x105 <0.01
2 μM (100x) 2.3 ± 0.3x104 1.5 ± 0.7x105
0.05% DMSO 1.9 ± 0.6x105 0.037 6.7 ± 2.0x105 0.04
1 μM (50x) 2.0 ± 0.3x104 1.3 ± 0.4x105
0.1% DMSO 4.3 ± 1.4x105 <0.01 9.2 ± 0.07x105 <0.01
0.2 μM (10x) 6.1 ± 4x104 1.8 ± 0.05x105
Pyrimethamine 1% EtOH 2.4 ± 0.8x105 <0.01 7.0 ± 1.7x105 <0.01
7.5 μM (10x) 9.3 ± 3.9x104 1.0 ± 0.2x105
0.5% EtOH 1.8 ± 0.1x105 0.06 7.1 ± 0.6x105 0.82
3.7 μM (5x) 1.3 ± 0.1x105 7.0 ± 0.7x105
1MCA: 3-dimensional multicellular aggregates.
2IC50: half maximal inhibitory concentration.
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0.2, 2 and 20 μM. Methotrexate inhibited the growth of
MCA in both cell lines. Disintegration of NCI-H295R
and SW-13 MCA occurred after 7 and 3 weeks of treat-
ment, respectively (Figure 4C and Table 3).
Pyrimethamine is also a DHFR inhibitor, used in
patients with protozoal infection such as toxoplasmosis.
The antiproliferative effect of pyrimethamine in mono-
layer cultures of NCI-H295R cells was observed only
when cells were treated with a concentration of 7.5 μM
(10 fold of IC50) (Figure 3D). At 7.5 μM (10 fold of IC50),
pyrimethamine demonstrated antiproliferative effect in
SW-13 cells (Figure 3E). Since the maximal serum level
of pyrimethamine is over 10 fold of IC50, we tested the
effect of pyrimethamine in MCA of both cell lines using
the concentrations of 3.7 and 7.5 μM (5 and 10 fold of
IC50). Pyrimethamine caused growth inhibition, and
resulted in significantly smaller and fewer MCA of NCI-
H295R and SW-13 cells at 7.5 μM concentration (10 fold
of IC50) but had no significant difference in size of MCA
when either cell line was treated with 3.7 μM pyrimeth-
amine (5 fold of IC50) (Figure 4D and Table 3).Effects of 4 candidate drugs on apoptosis
Caspase-3 and -7 activities were significantly higher in
NCI-H295R cells treated with 0.34 μM Bortezomib
(p <0.01) and 0.08 μM ouabain (p < 0.01), compared to
vehicle control groups, at 48 hours and 72 hours
(p = 0.02 and p = 0.01, respectively) (Figure 5). We
observed a lower caspase activity at 72 hours because
most cells were dead by 72 hours. There was no signifi-
cant difference in caspase activation when NCI-H295R
cells were treated with methotrexate (p = 0.32) and pyri-
methamine (p = 0.47) at 48 hours and 72 hours (p = 0.19
and p = 0.06, respectively) (Figure 5).
Effects of methotrexate and pyrimethamine on cell cycle
Increasing number of NCI-H295R cells in S-phase, from
28.5% to 46.7%, was observed when cells were treated with
0.2 μM (10 fold of IC50) methotrexate (Figure 6A). We
observed a modest increase in number of NCI-H295R
cells in S-phase, from 23.4% to 35.3%, when treated with
pyrimethamine (Figure 6B). However, we found that
7.5 μM pyrimethamine caused an increase in number of
SW-13 cells in S-phase, from 32.7% to 52.7% (Figure 6C).
Figure 5 Caspase-3 and -7 activity of NCI-H295R treated with bortezomib, ouabain, methotrexate, and pyrimethamine for 48 and
72 hours. The results were shown in the ratios of caspase activity in treated NCI-H295R to corresponding vehicle controls. Caspase activities of
treated cells were compared to respective vehicle controls. * p value <0.05 but≥ 0.01, ** p value < 0.01.
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Our study demonstrates an efficient and comprehensive
approach to identify compounds with antiproliferative
effect against ACC cells. We performed qHTS of a large,
clinically approved, pharmaceutical collection with the
goal to identify drugs that can be readily translated into
at least a phase II clinical trial. Initially, qHTS was per-
formed in NCI-H295R ACC cells which produce several
corticosteroids as well as characteristic ACC phenotypes
in vivo [20]. Of 21 high-confidence active compounds
from various therapeutic categories that had efficacy
greater than 60%; Bortezomib, ouabain, methotrexate
and pyrimethamine were validated in monolayer cultures
and MCA in both NCI-H295R and SW-13 cell lines. We
believe that MCA model using two authenticated ACC
cell lines used in this study better recapitulate in vivo
ACC tumor growth than just monolayer. Several import-
ant characteristics of solid tumors, including the devel-
opment of an extracellular matrix (ECM), cellular
junctions between epithelial cells are observed in MCA.
Similar to in vivo solid tumors, there are various concen-
trations of oxygen and nutrients as well as the different
rates of cell proliferation from the outer layer to thecenter which can result in central necrosis and regions
of hypoxia [21]. In addition, MCA have transcriptional
profiles that are more representative of solid tumor, dif-
ferent than monolayer culture [22].
Bortezomib binds the catalytic site of 26S prote-
asome and causes apoptosis by upregulating NOXA, a
proapoptotic protein and by suppressing nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB)
signaling pathway [23]. There are numerous ongoing
clinical trials using Bortezomib combined with various
other agents in several types of solid tumors, some
with promising initial results [24]. We have validated
the antineoplastic effect of bortezomib in both NCI-
H295R and SW-13 cell lines in monolayer culture and
MCA. Our results also suggest that Bortezomib causes
apoptosis in NCI-H295R cells.
Ouabain is a cardiac glycoside that inhibits cell mem-
brane Na+/K + ATPase at high concentrations. In
addition to an inotropic effect, cardiac glycosides have
been explored for their antineoplastic effect [25-29]. Po-
tential mechanisms for antineoplastic effect of cardiac
glycosides include alteration of homeostasis of sodium,
potassium and calcium, inhibition of topoisomerase II,
Figure 6 (See legend on next page.)
Nilubol et al. Journal of Translational Medicine 2012, 10:198 Page 12 of 15
http://www.translational-medicine.com/content/10/1/198
(See figure on previous page.)
Figure 6 Flow cytometry demonstrated that methotrexate caused S-phase cell cycle arrest in NCI-H295R (A) and pyrimethamine
resulted in a modest increase of NCI-H295R cells in S-phase (B). Pyrimethamine caused S-phase cell cycle arrest in SW-13 (C).
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[29]. Although cardiac glycosides can cause cytotoxicity
and inhibit protein synthesis in non-malignant cells [30],
some studies suggest that cancer cells are more suscep-
tible to the antiproliferative effect of cardiac glycosides
[31,32]. The results from our qHTS showed that several
cardiac glycosides active against ACC cells had excellent
efficacy. However, most of these drugs had IC50 at serum
concentrations which would be associated with toxicity
in humans. In patients with breast cancer, an anticancer
activity of digitalis has been observed [33-36], which is
consistent with in vitro experiments that showed that the
anticancer effects of cardiac glycosides in breast cancer
cells can be achieved at the concentrations close or at
therapeutic plasma levels [37-39]. We demonstrated that
ouabain has a potent antiproliferative effect against NCI-
H295R cells at clinically achievable concentration in both
monolayer cultures and MCA, and causes apoptosis. A
similar effect was observed in SW-13 MCA at IC50 and
higher concentrations. Methotrexate and pyrimethamine
are both DHFR inhibitors. Methotrexate has been used
clinically as an anticancer drug and immunomodulator
for over 50 years. The antineoplastic effect of pyrimeth-
amine has been recently demonstrated in melanoma by
inducing apoptosis [40,41]. On the other hand, pyrimeth-
amine was reported to stimulate the growth of breast
cancer cells (MCF-7) [42]. We did not find Methotrexate
and pyrimethamine cause significant activation of cas-
pase 3 and 7 or morphologic changes in monolayer cul-
ture. The antiproliferative effect of both DHFR inhibitors
in ACC cells is likely due to a disruption of thymidylate
and purine nucleotide biosynthesis during the S-phase
of cell cycle [43]. The result from cell cycle analysis
in NCI-H295R cells treated with methotrexate was
consistent with S-phase cell cycle arrest as previously
reported by others [44,45]. Similarly, we observed an
increase of pyrimethamine treated SW-13 cells in S-
phase, consistent with a disruption of DNA synthesis
caused by DHFR inhibitor [40,46]. Both methotrexate
and pyrimethamine had antiproliferative effect at 10
fold of IC50 concentration in monolayer cultures. The
difference observed in MCA occurred after several
weeks of exposure.
Since pyrimethamine and methotrexate have high
therapeutic margins, a higher concentration (10 fold and
100 fold of IC50, respectively) can be administered.
Growth inhibition of SW-13 and NCI-H295R MCA
treated with high concentration of pyrimethamine (10
fold of IC50) was observed.To our knowledge, this is the first study to use such a
large collection of clinical drugs to test antiproliferative
effect in ACC cells. These findings support the utility of
qHTS of clinical drug library as a feasible approach for
screening drug activity in other cancer cell lines from
various other solid and hematologic malignancies. Be-
cause the costs and resources required for developing a
new drug for rare cancers, such as ACC, are often pro-
hibitive, the qHTS is an excellent, relatively inexpensive
approach to identify effective agents in a short period of
time. The discovery of new anticancer drugs using well-
known compounds has several important implications.
Patients with locally advanced and/or metastatic ACC
could benefit from the identification of clinically
approved agents that show anticancer effect specific to
ACC cells and the prompt development of clinical trials
to test the efficacy of these compounds can be initiated
in relatively shorter time compared to the time required
to bring unapproved compounds to clinical trials. An
in vivo testing may still be necessary to identify the most
effective drugs and or combination and to assess the dif-
ferent toxicity profile generated by drug combination
treatment. Because drug toxicity is a common reason for
discontinuation of therapy and poor compliance to the
treatment, screening of existing drugs for new activity
may be helpful because the toxicity of these drugs is well
characterized and the most effective agents with the low-
est toxicity profile can be selected. The toxicity may also
be predicted and mitigated by using various countermea-
sures known for specific drugs. Furthermore, agents with
clinical achievable concentrations can be determined
after qHTS and the selection of those agents with potent
activity well below the clinical sustained and peak con-
centrations of a drug is also a very attractive approach to
use for cancer therapeutics. Even drugs that have IC50
above maximal serum level could possibly be adminis-
tered locally or regionally, such as catheter-based treat-
ment of metastasis confined to the liver, to reduce
systemic toxicity.
In addition, many of the known drugs have well docu-
mented mechanism of actions which can be further
explored to help understand tumor biology and path-
ways associated with tumor initiation and progression.
The insight gained from altered molecular pathways may
be used to create more effective drugs with less toxicity.
Drug mechanism of action or therapeutic category en-
richment analysis of active drugs can help identify
mechanisms or pathways involved in tumor genesis. The
common mechanism among the active drugs in our
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found 8 of 21 most effective drugs against NCI-H295R
identified by qHTS were cardiac glycosides (Table 2).
Our study is the first to describe in vitro antiproliferative
effect of cardiac glycosides in ACC cells. Several other
studies have reported in vitro and in vivo antiprolifera-
tive and apoptotic effects of these drugs in solid and
hematologic cancer cell lines [29]. The enrichment ana-
lysis of active drugs can also be helpful in population-
based study to evaluate cancer-risk reduction associated
with specific drug use found to be active in our screen-
ing assay. Recently, guided by the results of their qHTS
in prostate cancer cells, Platz, et al demonstrated that
chronic Digoxin users have 25% lower risk of developing
prostate cancer [8].
We have demonstrated that qHTS is an efficient
method to identify active drugs against cancer cells;
however, qHTS may not be able to identify drugs that
may have activity after 48 hours of treatment. Because
each well in the 1536-well plate contains only 5 μL, an
incubation time longer than 48 hours would have signifi-
cant evaporative loss and would result in inconsistent
drug concentrations and high degree of variation.
One of the limitations in this study is not being able to
generate primary cultures of human ACC with sufficient
cell number and propagation to test. Only NCI-H295R
cell line was screened with qHTS and screening multiple
cell lines may identify additional active drugs. Further-
more, qHTS in multiple ACC cell lines can demonstrate
the antineoplastic spectrum of the active compounds
and a subset of high-efficacy compounds that are active
across most ACC cell lines may be chosen for further
validation. In summary, we have identified 79 active
compounds from various therapeutic categories against
ACC cell lines using a qHTS of clinical drug library
screening approach. Four promising drugs (bortezomib,
ouabain, methotrexate and pyrimethamine) were vali-
dated. The current study shows promising results in
MCA treated with single candidate drug. Our results
support the use of qHTS of clinical pharmaceutical li-
braries in different cancer types to identify drugs with
potent activity that can be readily translated into clinical
trials for patients with incurable malignancies or those
with cancers refractory to standard therapy.
Conclusions
qHTS of previously approved compounds is an effective
strategy to identify candidate drugs with antineoplastic
activity. We have validated the antineoplastic effect of
bortezomib, ouabain, methotrexate and pyrimethamine
in 2 ACC cell lines which can be translated into phase II
clinical trials in patients with locally advanced and/or
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